STAT

‘On a knife edge’: Ebola outbreak threatens to escalate as violence rises

As violence aimed at response workers increases, the #Ebola outbreak in the Congo threatens to spiral out of control.
Doctors and health workers marched in the Eastern Congo town of Butembo in April, after attackers shot and killed an epidemiologist from Cameroon who was working for the WHO.

The Ebola outbreak in the Democratic Republic of the Congo is threatening to spiral out of control, with ongoing violence aimed at the Ebola response workers undermining efforts to stop spread of the deadly virus.

STAT spoke to a number of experts involved with or closely monitoring the situation to try to get a sense of where the outbreak in northeastern DCR is heading.

Each one agreed: A disaster is unfolding.

“The numbers in the last month have been horrifying,” said Dr. Jeremy Farrar, director of the Wellcome Trust, a major funder of the Ebola response. “It’s on a knife edge. I’m not sure how else to describe it, really.”

The World Health Organization is doing scenario mapping trying to figure out just how bad this outbreak might become. But Dr. Mike Ryan, executive director of the emergencies program, won’t share what they see as they look at their models. “That’s for planning purposes, not for speculation,” Ryan insisted in an interview with STAT on Monday.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks